Theratechnologies, Inc. (THTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
THTX Stock Summary
- Theratechnologies Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 88.78% of US listed stocks.
- THTX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 75.9% of US stocks.
- Theratechnologies Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -17.82%, greater than the shareholder yield of only 19.35% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Theratechnologies Inc are CRNT, AMKR, KMDA, SPNS, and SONM.
- Visit THTX's SEC page to see the company's official filings. To visit the company's web site, go to www.theratech.com.
THTX Price Target
For more insight on analysts targets of THTX, see our THTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $4.00 | Average Broker Recommendation | 1.75 (Moderate Buy) |
THTX Stock Price Chart Interactive Chart >
THTX Price/Volume Stats
| Current price | $2.44 | 52-week high | $4.46 |
| Prev. close | $2.49 | 52-week low | $2.05 |
| Day low | $2.25 | Volume | 48,100 |
| Day high | $2.50 | Avg. volume | 78,356 |
| 50-day MA | $2.49 | Dividend yield | N/A |
| 200-day MA | $3.08 | Market Cap | 232.10M |
Theratechnologies, Inc. (THTX) Company Bio
Theratechnologies, Inc. is a specialty pharmaceutical company that discovers and develops therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. The Company's main product is being marketed in the United States for the reduction of excess abdominal fat n HIV-infected patients with lipodystrophy.
Latest THTX News From Around the Web
Below are the latest news stories about Theratechnologies Inc that investors may wish to consider to help them evaluate THTX as an investment opportunity.
Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update- FY2021 consolidated sales grew 5.7% supported by strong EGRIFTA SV® sales - Second half fiscal 2021 revenues grew 10% over 2020, while total new enrollments grew 24% as commercial execution strategy firmly carries momentum into 2022 - Lead oncology asset TH1902 trial advances towards establishing MTD and initiation of larger Phase 1/Part B expansion (basket trial) - Company announces revenue guidance of US$79M to US$84M for Fiscal 2022 MONTREAL, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Theratechnolog |
Theratechnologies Presents Results From Trogarzo® IV Push Administration Study at CROI 2022No difference in pharmacokinetics between IV Push and IV InfusionNo serious adverse events observedNo difference in viral load between IV Push and IV Infusion and no anti-drug antibodies detected MONTREAL, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the presentation of positive results from the Phase 3 |
Theratechnologies Strengthens Global Commercial Capabilities by Launching Internal Field Force- Top Performing U.S. Based Key Account Managers, Medical Sales Liaisons, and Community Liaisons to join Theratechnologies’ from its current partner contract sales organization - Higher employee engagement and retention, greater ability to attract top talent and lower turnover rate expected from the move MONTREAL, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and com |
Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021MONTREAL, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its fourth quarter of fiscal 2021 ended November 30, 2021 as well as for its full fiscal year 2021 on Thursday, February 24, 2022. A conference call will be held on February 24, 2022 at 8:30 a.m. (ET) to discuss the results and |
Theratechnologies (TSE:TH) three-year losses have grown faster than shareholder returns have fallen, but the stock pops 11% this past weekThis week we saw the Theratechnologies Inc. ( TSE:TH ) share price climb by 11%. But that doesn't change the fact that... |
THTX Price Returns
| 1-mo | -3.94% |
| 3-mo | -18.39% |
| 6-mo | N/A |
| 1-year | -33.33% |
| 3-year | -46.18% |
| 5-year | -51.10% |
| YTD | -19.47% |
| 2021 | 21.20% |
| 2020 | -24.24% |
| 2019 | -45.90% |
| 2018 | 6.41% |
| 2017 | 175.59% |
Loading social stream, please wait...